研究と業績
research and achievements

北海道大学病院乳腺外科は、患者中心の医療を実践することを第一に考えています。それに加えて論文、学会発表などの学術活動も重要なテーマの一つです。研修医、専門医、スタッフ等それぞれの成長に応じた活動を行うことで、日本の乳がんの臨床に貢献するとともに、患者さんに正しい情報を伝える力をチーム全体で高めて行きたいと思っています。

論文
国際学会
全国学会
地方学会

論文および著書paper

2024年

  • Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kommel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P.
    Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Ann Oncol. Epub ahead of print.
  • Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, Barrios C, McIntyre K, Wei R, Munoz M, Antonio BS, Liepa AM, Martin M, Johnston SRD, Kellokumpu-Lehtinen PL, Harbeck N
    Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Eur J Cancer 199:113555. 2024
  • Takahashi M, Osako T, Yasojima H, Inoue K, Kawashima M, Maeda H, Ichikawa A, Muramatsu Y, Masuda N.
    Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
    Breast Cancer. 31:53-62,2024
  • 木下貴之、高橋將人
    ラジオ波焼灼療法の適正使用指針
    乳癌の臨床 39:51-59, 2024

2023年

  • Takahashi M, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Denkert C, Park YH, Im SA, Ahn JH, Mukai H, Huang CS, Chen SC, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P
    Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
    JAMA Netw Open . 6(11):e2342107, 2023
  • Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K.
    Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
    J Clin Oncol. 41:5550-5560, 2023
  • Moriya Y, Oshino T, Hosoda M, Shikishima K, Shun Miura, Jun Muto, Tatsuya Kato, Takahashi M
    A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment
    Case Rep Oncol 16 (1): 791–796, 2023
  • Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T.
    Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
    J Immunother Cancer. 2023 Sep;11(9):e007126.
  • Masuda H, Tanabe Y, Sakai H, Matsumoto K, Shimomura A, Doi M, Miyoshi Y, Takahashi M, Sagara Y, Tokunaga S, Iwasa T, Niikura N, Yoshimura K, Takano T, Tsurutani J.
    Efficacy of probiotics and trimebutine maleate for abemaciclib- induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
    Breast. 71:22-28, 2023
  • Takada S, Maeda H, Umehara K, Kuwahara S, Yamamoto M, Tomioka N, Takahashi M, Watanabe K, Hashishita H.
    Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
    Asian Pac J Cancer Prev. 24(6):1955-1962, 2023
  • Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, Amano T, Yuki S, Komatsu Y, Osawa T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Matsuno Y, Manabe A, Sakurai A, Ishiguro A, Takahashi M, Yokouchi H, Naruse H, Mizukami Y, Dosaka-Akita H, Kinoshita I.
    Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
    Cancer Sci 114(8):3385-3395, 2023
  • Iwai T, Nishida M, Kudo Y, Omotehara S, Kato K, Takakuwa E, Shimizu A, Kato F, Hosoda M, Takahashi M, Teshima T.
    A case of breast angiosarcoma clearly delineated by contrast-enhanced ultrasonography.
    J Clin Ultrasound. 51(6):1048-1050, 2023
  • Tomioka N, Hatanaka KC, Okuyama D, Watanabe KI, Yamamoto M, Maeda H, Tachikawa H, Kuwahara S, Shimizu A, Suzuki H, Hatanaka Y, Takahashi M
    Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer 30(3):497-505, 2023
  • Saito Y, Takekuma Y, Takeshita T, Oshino T, Sugawara M.
    Dexamethasone dose- dependently prevents taxane-associated acute pain syndrome in breast cancer treatment.
    Support Care Cancer. 31(6):372, 2023
  • Saito Y, Kanno R, Takekuma Y, Takeshita T, Oshino T, Sugawara M.
    High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment.
    Sci Rep. 13(1):9247, 2023
  • Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M,Imanishi S, Hashimoto A, Wada H, Seino KI.
    Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. Cancer Immunol Immunother.
    Cancer Immunol Immunother. 72(4):851-864, 2023

2022年

  • Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Toyama T, Tsugawa K, Kawahara T,Mukai H
    RESPECT study group. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
    Breast 66:245-254, 2022
  • Abe Y, Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H,Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T,Takashima T, Aihara T, Mukai H, Hara F, Shien T, Doihara H, Toyooka S.
    Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of aRandomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
    Acta Med Okayama. 76(6):661-671, 2022
  • Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T,Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N.
    Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
    PLoS One 17(11):e0278344, 2022
  • Kotani H, Masuda N, Yamashita T, Naito Y, Taira T, Inoue K, Takahashi M, Yonemori K, Toyoizumi S, Mori Y, Nagasawa T, Hori N, Iwata H.
    Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Breast Cancer 29(6):1088-1098, 2022
  • Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H,Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T.
    Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer.
    Data Brief 45:108558, 2022
  • Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K,Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S.
    Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized,open-label phase III study (PRECIOUS).
    Cancer Sci 113(9):3169-3179, 2022
  • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba,T, Kadoya, T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M
    Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    BMC Med 20:136, 2022
  • Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M
    Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
    Clin Drug Investig 42:253-262, 2022
  • Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M
    Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast Cancer 29:174-184, 2022
  • Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, Kikawa Y, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Takashima T, Aihara T, Mukai H, Hara F
    Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer 29:131-143, 2022
  • Shimizu N, Myojin M, Tamura M, Nishiyama N, Yamashiro K, Yuyama Y, Okazaki Y, Suzuki Y, Takahashi M
    Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
    J Radiat Res 63:80-87, 2022
  • Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kommel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med 386:556-567, 2022
  • Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T
    Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Eur J Cancer 171:193-202, 2022
  • Minoura Y, Takahashi M, Maeda H, Kuwahara S, Tachikawa H, Yamamoto M, Tomioka N, Watanabe K, Sakurai A
    Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Breast Cancer, 2022
  • Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmaea J
    Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
    Breast Cancer 29:92-102, 2022
  • Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y.et al
    Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
    Support Care Cancer 30:4505-4514, 2022
  • 高橋將人
    【新任教授寄稿】乳腺外科治療過去の変遷と新生乳腺外科教室として我々がめざすアプローチ
    北海道医誌　97：23-25,2022
  • 高橋將人
    周術期早期乳がん補助薬物療法の新たなる展開　Monarch E試験
    癌と化学療法　49(12):1321-1323, 2022
  • 高橋將人
    乳癌の薬物療法　転移再発乳癌の治療
    臨床と研究　99(8):975-979, 2022
  • 高橋將人、吉波哲大、上本剛、御手洗幸子、田辺記子、坂本はと恵、牧原玲子
    がんゲノム医療時代の多職種連携　
    腫瘍内科　30(1):98-102, 2022

2021年

  • Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S
    Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
    Breast Cancer 28:145-160, 2021
  • Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N.
    The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
    Breast Cancer Res Treat. 185(1):125-134, 2021
  • Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H
    Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast 55:63-68, 2021
  • Takahashi M, Inoue K, Mukai H, Yamanaka T, Egawa C, Miyoshi Y, Sakata Y, Muramoto K, Ikezawa H, Matsuoka T, Tsurutani J
    Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Breast Cancer 28:945-955, 2021
  • Taira N, Sawaki M, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Ohashi Y, Mukai H, Kawahara T; RESPECT Study Group.
    Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
    J Clin Oncol 39:2452-2462, 2021
  • Nakayama T, Yoshinami T, Yasojima H, Kittaka N, Takahashi M, Ohtani S, Kim SJ, Kurakami H, Yamamoto N, Yamada T, Takata T, Masuda N
    Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
    BMC Cancer 21:795, 2021
  • Mukai H, Uemura Y, Akabane H, Watanabe T, Park Y, Takahashi M, Sagara Y, Nishimura R, Takashima T, Fujisawa T, Hozumi Y, Kawahara T
    Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
    Br J Cancer 125:1217-1225, 2021
  • Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M
    Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Breast Cancer Res Treat 188:117-131, 2021
  • Inoue K, Masuda N, Iwata H,Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J, Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW Jr, Toi M
    Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Breast Cancer 28:1038-1050, 2021
  • Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N
    Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
    Breast Cancer Res Treat 188:675-683, 2021
  • Chen Y, Noma S, Taguchi Y, Takahashi M, Tsurutani J, Mori S, Sakaguchi S, Asou H, Tomii K
    Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
    Breast Cancer 28:710-719, 2021
  • André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pepai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS
    Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    Ann Oncol 32:208-217, 2021
  • 高橋將人
    どさんこドクターに聞く　教えて北海道のがん
    亜璃西社、　札幌　2021
  • 高橋將人
    高齢者乳がんの診断フロー
    20-22 (澤木正孝、佐治重衡:高齢者の乳がん診療,151p,南江堂, 東京,2021

2020年

  • Yamashita S, Hattori N, Fujii S, Yamaguchi T, Takahashi M, Hozumi Y, Kogawa T, El-Omar O, Liu YY, Arai N, Mori A, Higashimoto H, Ushijima T, Mukai H
    Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
    Sci Rep 10:15530, 2020
  • Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S
    Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Trials 21:391, 2020
  • Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M
    Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
    Jpn J Clin Oncol 50:3-11, 2020
  • Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y
    CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study
    J Clin Oncol 38:558-566, 2020
  • Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, Hashigaki S, Muramatsu Y, Umeyama Y, Toi M
    Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
    Cancer Med 9:4929-4940, 2020
  • Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T
    The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
    Breast Cancer 27:322-331, 2020
  • Schmid P, Cortes J, Pusztai L, McArthur H, Kommel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators.
    Pembrolizumab for Early Triple-Negative Breast Cancer.
    N Engl J Med 382:810-821, 2020
  • Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H
    Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
    J Clin Oncol 38:3743-3752, 2020
  • Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A
    Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
    J Clin Oncol 38:3138-3149, 2020
  • Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y
    Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
    Br J Cancer 122:1747-1753, 2020
  • Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K, Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, Saeki T
    A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Cancer Med 9:3319-3327, 2020
  • Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N
    The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
    Breast Cancer 27:973-981, 2020
  • Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M
    A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Breast Cancer Res Treat 180:715-724, 2020
  • Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M
    JBCRG-C01 Collaborative Group. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Breast Cancer. 27(4):631-641, 2020
  • Inoue K, Takahashi M, Mukai H, Yamanaka T, Egawa C, Sakata Y, Ikezawa H, Matsuoka T, Tsurutani J
    Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
    Invest New Drugs 38:1540-1549, 2020
  • 高橋將人
    -乳癌診療ガイドライン(2018年版)のエッセンスと改訂ポイントの解説-
    北海道外科雑誌 65:41-45, 2020
  • 髙橋將人
    各分野のガイドラインを紐解く　乳癌診療ガイドライン(2018年版)　そのエッセンスと改訂ポイントの解説
    日本外科学会雑誌 121:395-395, 2020

学会発表presentations

国際学会

2024年

2023年

  • Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue, Masahiro Kawashima, Hideki Maeda, Mitsuya Ito, Yasuaki Sagara, Kan Yonemori, Masaya Hattori, Naohito Yamamoto, Eriko Tokunaga, Shozo Ohsumi, Yutaka Yamamoto, Akemi Ichikawa, Yasuaki Muramatsu, Norikazu Masuda
    Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2- advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)
    San Antonio Breast Cancer Symposium Dec. 06
  • Hosoda M, Takahashi M, Baba M, Oshino T, Moriya Y, Shikishima K
    Scalp cooling system for breast cancer patients treated by adjuvant or neo-adjuvant chemotherrapy.
    The 18Th St.Gallen International Breast Cancer Conference　Mar. 2023

2022年

2021年

2020年

全国学会

2024年

  • Masato Takahashi, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Theodoros Foukakis, Marie-Ange Mouret-Reynier, Marta Ferreira, Seock-Ah Im, Michael Untch, Peter A. Fasching, Fatima Cardoso, Yu Ding, Wilbur Pan, Jaime Mejia, Joyce O’Shaughnessy, Peter Schmid
    Neoadjuvant Pembrolizumab + Chemo vs Placebo + Chemo Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC
    第21回日本臨床腫瘍学会学術集会　2024年2月　名古屋
  • Masato Takahashi, Yutaka Yamamoto, Hiroji Iwata, Tetsuhiro Yoshinami, Tatsuya Toyama, Takayuki Ueno, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Naruto Taira, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda on behalf of the PRECIOUS Study Group
    OS results from the PRECIOUS (JBCRG-M05): Pertuzumab retreatment for HER2-positive advanced breast cancer patients
    第21回日本臨床腫瘍学会学術集会　2024年2月　名古屋

2023年

  • 押野智博、遠田建、清水寛和、荒町優香里、小金澤千夏、羽田光輝、守谷結美、細田充主、 加藤扶美、工藤與亮、岩崎倫政、高橋將人
    人工知能を用いた造影超音波検査による、原発性乳癌腋窩リンパ節転移の診断能の検証
    第61回日本癌治療学会学術集会　2023年10月　横浜
  • 守谷結美、押野智博、細田充主、敷島果林、高橋將人
    ベバシズマブ併用化学療法中に気胸を発症し、外科治療を要した乳癌の１例
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 別所光、押野智博、細田充主、守谷結美、敷島果林、高橋將人
    両側乳房全摘術を施行した巨大乳房肥大症の１例
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 敷島果林、守谷結美、押野智博、細田充主、高橋將人
    CDK4/6阻害薬使用後の後治療についての検討
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 押野智博、敷島果林、守谷結美、細田充主、高橋將人
    乳癌術後に小脳症状が改善した、抗神経抗体陰性の傍腫瘍性神経症候群の１例
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 玉那覇朝雄、押野智博、細田充主、守谷結美、敷島果林、高橋將人
    腋窩リンパ節腫大を契機に発見されたBRCA遺伝子変異陰性の若年発症の男性乳癌の一例
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 細田充主、敷島果林、守谷結美、押野智博、高橋將人
    化学療法による脱毛抑制を目的とした保冷剤を用いた新規頭皮冷却システム「愛帽」の検討
    第31回日本乳癌学会学術総会2023年6月　横浜
  • 長安健、押野智博、細田充主、守谷結美、敷島果林、高橋將人
    BRCA1病的バリアントを有する乳癌患者の術後１年目に乳腺血管肉腫を発症した１例
    第31回日本乳癌学会学術総会2023年6月　横浜

2022年

  • 押野智博、敷島果林、守谷結美、細田充主、高橋將人
    The prognosis of breast cancer patients without axillary dissection who has macro sentinel lymph node metastasis-Analysis of our hospital
    第60回日本癌治療学会学術総会　2022年10月神戸
  • 押野智博、竹下卓志、守谷結美、加藤扶美、高橋將人
    深層学習を用いた造影超音波による原発性乳癌の腋窩リンパ節診断能の検討
    第30回日本乳癌学会学術総会 2022年7月　横浜
  • 細田充主
    周術期化学療法における頭皮冷却の効果に関する検討　
    第30回日本乳癌学会学術総会 2022年7月　横浜
  • 敷島果林、市之川一臣、熊谷健太郎、林真理子、武内慎太郎、道免寛充、岩村八千代、山田秀久、高桑康成
    術後22年目に十二指腸転移をきたした乳腺小葉癌の1例
    第30回日本乳癌学会学術総会 2022年7月　横浜
  • Masato Takahashi, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather McArthur; Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Seock-Ah Im, Jin-Hee Ahn, Hirofumi Mukai, Chiun-Sheng Huang, Shin-Cheh Chen, Min Hwan Kim, Liyi Jia Xin Tong Li, Konstantinos Tryfonidis, Vassiliki Karantza, Hiroji Iwata, Peter Schmid
    Neoadjuvant Pembrolizumab/Placebo + Chemo, Followed by Adjuvant Pembrolizumab/Placebo in Early TNBC: KEYNOTE-522 Asian Subgroup
    第19回日本臨床腫瘍学会学術集会 2022年2月　京都

2021年

  • Masato Takahashi
    Current strategy of neoadjuvant chemotherapy and surgical management in breast cancer : Indication and Practice in Korea and Japan
    第29回日本乳癌学会学術総会GBCC（KBCS）/ JBCS Joint Session 2021年7月　横浜
  • 細田充主
    周術期化学療法における頭皮冷却装置PAXMANの検討
    第29回日本乳癌学会、横浜
  • 押野 智博、萩尾 加奈子、守谷 結美、李 東、加藤 扶美、竹下 卓志
    eposter：原発性浸潤性乳癌 362 例の、造影超音波による腋窩リンパ節の転移評価の後ろ向き検討
    第29回日本乳癌学会学術総会 2021年7月
  • 守谷 結美、押野 智博、竹下 卓志、萩尾 加奈子、李 東、山下 啓子
    eposter：当院で経験した妊娠期乳癌の 2 例
    第29回日本乳癌学会学術総会 2021年7月
  • 李 東、竹下 卓志、萩尾 加奈子、守谷 結美、押野 智博
    eposter：特発性血小板減少性紫斑病併発下に手術療法、術後化学療法を施行した乳癌の 2 例
    第29回日本乳癌学会学術総会 2021年7月

2020年

  • 高橋將人, 増田慎三, 吉波哲大, 八十島宏行, 橘高信義, 大谷彰一郎, 金昇晋, 倉上弘幸, 山本尚子, 山田知美, 高田武彦, 中山貴寛
    HER2陽性転移性乳癌におけるT-DM1治療直後の薬物療法の有効性　KBCSG-TR1917観察研究
    第28回日本乳癌学会、2020年10月 名古屋
  • 細田充主
    閉経後ER陽性HER2陰性乳癌に対する術前レトロゾール1年間投与の検討
    第28回日本乳癌学会、2020年10月
  • 押野　智博、竹下　卓志、萩尾加奈子、鈴木はる菜、守谷　結美、 山下　啓子
    術前に非浸潤性乳管癌と診断されたが、術後に化学療法を要し た症例の臨床病理学的検討
    第28回日本乳癌学会総会 2020年10月
  • 李　東、押野 智博、竹下　卓志、萩尾　加奈子、守谷　結美、山下　啓子
    臓器移植術後、免疫抑制剤内服中に両側乳癌を発症した2例
    第28回日本乳癌学会総会 2020年10月

地方学会

2024年

2023年

  • 小金澤千夏、細田充主、荒町優香里、李東、守谷結美、羽田光輝、押野智博、高橋將人
    持続型G-CSF製剤投与により大動脈炎をきたした１例
    第112回北海道外科学会 2023年9月
  • 荒町優香里、細田充主、小金澤千夏、李東、守谷結美、羽田光輝、押野智博、高橋將人
    右乳癌術後25年経過し、肺転移を指摘された１例
    第21回日本乳癌学会北海道地方会 2023年9月
  • 小金澤千夏、細田充主、荒町優香里、李東、守谷結美、羽田光輝、押野智博、高橋將人
    Abemaciclibにより脳転移がコントロールされていた１例
    第21回日本乳癌学会北海道地方会 2023年9月
  • 守谷結美、押野智博、細田充主、羽田光輝、李東、小金澤千夏、荒町優香里、高橋將人
    造影CTでは検出できなかったびまん性肝転移を認めた乳癌の２例
    第21回日本乳癌学会北海道地方会 2023年9月
  • 羽田光輝、細田充主、荒町優香里、小金澤千夏、李東、守谷結美、押野智博、高橋將人、亀田博
    当科でOncotype DXを施行した症例の検討
    第21回日本乳癌学会北海道地方会 2023年9月

2022年

  • 押野智博、敷島果林、守谷結美、細田充主、高橋將人
    乳癌腋窩リンパ節マクロ転移時の腋窩郭清省略省略に関する、当科での予後の検討
    第20回日本乳癌学会北海道地方会 2022年9月
  • 守谷結美、押野智博、細田充主、敷島果林、高橋將人
    当院で経験した潜在性乳癌の３例
    第20回日本乳癌学会北海道地方会 2022年9月
  • 敷島果林、押野智博、守谷結美、細田充主、高橋將人
    治療関連骨髄異形成症候群を有した乳癌の１例
    第20回日本乳癌学会北海道地方会 2022年9月
  • 細田充主、敷島果林、守谷結美、押野智博、高橋將人
    ER陽性HER2陰性転移再発乳がんに対するCDK４/６阻害剤使用後の治療についての検討
    第20回日本乳癌学会北海道地方　2022年9月

2021年

  • 押野　智博、守谷　結美、竹下　卓志
    当科でのエリブリン使用経験
    第19回日本乳癌学会北海道地方会 2021年10月

2020年

  • 押野　智博、竹下　卓志、萩尾加奈子、守谷　結美、 李　東、山下　啓子
    骨転移が9年間の内分泌療法で完全奏効となり、その後9年間完全奏効を維持している再発乳癌の1例
    第18回日本乳癌学会北海道地方会 2020年9月（誌上開催）
  • 守谷　結美、押野　智博、竹下　卓志、萩尾加奈子、李　東、山下　啓子
    男性乳癌の2例
    第18回日本乳癌学会北海道地方会 2020年9月（誌上開催）
  • 李　東、押野 智博、竹下　卓志、萩尾　加奈子、守谷　結美、山下　啓子
    術前薬物療法中に脊髄小脳変性症を発症した乳癌の１例
    第18回日本乳癌学会北海道地方会 2020年9月（誌上開催）